Education
About Us
Working with TipRanks
Follow Us
Kiniksa Pharmaceuticals (KNSA)
NASDAQ:KNSA
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 423.24M | $ 270.26M | $ 220.18M | $ 38.54M | $ 0.00 |
| Gross Profit | $ 362.33M | $ 213.74M | $ 173.21M | $ 29.44M | $ -3.81M |
| Operating Income | $ -45.62M | $ -25.20M | $ 7.37M | $ -156.64M | $ -157.36M |
| EBITDA | $ -45.62M | $ -22.86M | $ 9.77M | $ -154.28M | $ -152.42M |
| Net Income | $ -43.19M | $ 14.08M | $ 183.36M | $ -157.92M | $ -161.38M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 243.63M | $ 206.37M | $ 190.61M | $ 182.20M | $ 323.48M |
| Total Assets | $ 580.55M | $ 526.32M | $ 459.67M | $ 232.80M | $ 349.46M |
| Total Debt | $ 9.86M | $ 12.26M | $ 5.92M | $ 6.05M | $ 6.99M |
| Net Debt | $ -173.73M | $ -95.70M | $ -116.80M | $ -116.42M | $ -107.05M |
| Total Liabilities | $ 142.12M | $ 87.48M | $ 63.52M | $ 47.76M | $ 37.53M |
| Stockholders' Equity | $ 438.44M | $ 438.84M | $ -492.03M | $ -675.40M | $ -517.47M |
| Cash Flow | |||||
| Free Cash Flow | $ 25.41M | $ 13.17M | $ 5.70M | $ -146.71M | $ -136.81M |
| Operating Cash Flow | $ 25.69M | $ 13.30M | $ 5.81M | $ -126.30M | $ -136.53M |
| Investing Cash Flow | $ 37.67M | $ -29.56M | $ -8.08M | $ 128.63M | $ -23.44M |
| Financing Cash Flow | $ 12.27M | $ 1.50M | $ 2.52M | $ 5.88M | $ 227.09M |